Skip to main content
SpringerLink
Log in

Pharmacological Management of Schizophrenia in Older Patients

  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Although antipsychotic drugs are the mainstay of treatment in older patients with schizophrenia, much of the theoretical work underpinning their use is based on evidence gained from younger patients. With respect to dosages, there has been little work comparing plasma concentrations of antipsychotics in older patients with those of younger patients. However, there are well documented changes in the pharmacokinetics of these drugs in the elderly, particularly in their hepatic metabolism and renal excretion. There is also evidence that older patients experience more adverse effects from antipsychotics than younger patients. Such effects include extrapyramidal symptoms, postural hypotension and falls. For these reasons it is recommended that starting doses of antipsychotic drugs in older patients should be in the region of 25 to 50% of that recommended for younger patients, and should be slowly increased. Selection of a particular antipsychotic agent is best made on the basis of individual patient characteristics and the adverse effect profiles of particular drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris JM, Jeste DV. Late onset schizophrenia: an overview. Schizophr Bull 1988; 14; 39–55

    PubMed  CAS  Google Scholar 

  2. Kraepelin E. Dementia praecox and paraphrenia (1919). Translated by Barclay RM. New York: Robert E. Kreiger, 1971

    Google Scholar 

  3. Mayer W. On paraphrenic psychoses. Z Gesamte Neurol Psychiatr 1921; 71: 187–206

    Article  Google Scholar 

  4. Bleuler E. Dementia praecox or the group of schizophrenias (1911). Translated Zinkin J. New York: International University Press, 1950

    Google Scholar 

  5. Roth M. The natural history of mental disorder in old age. J Ment Sci 1955; 101:281–301

    PubMed  CAS  Google Scholar 

  6. American Psychiatric Association. DSM III: diagnostic and statistical manual of mental disorders. 3rd ed. Washington DC: The Association, 1980

    Google Scholar 

  7. American Psychiatric Association. DSM IHR: diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington DC: The Association, 1987

    Google Scholar 

  8. American Psychiatric Association. DSM IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: The Association; 1994

    Google Scholar 

  9. World Health Organization. The ICD 10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992

    Google Scholar 

  10. Quintal M, Day-Cody D, Levy R. Late paraphrenia and ICD 10. Int J Geriatr Psychiatry 1991; 6: 111–6

    Article  Google Scholar 

  11. Almieda OA, Howard R, Forstl H, et al. Should the diagnosis of late paraphrenia be abandoned? Psychol Med 1992; 22: 11–4

    Article  Google Scholar 

  12. Yassa R, Suranyi-Cadotte B. Clinical characteristics of late-onset schizophrenia and delusional disorder. Schizophr Bull 1993; 19: 4: 701–7

    PubMed  CAS  Google Scholar 

  13. Heritch, AJ. Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophr Bull 1990; 16: 605–15

    PubMed  CAS  Google Scholar 

  14. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133–52

    Article  PubMed  CAS  Google Scholar 

  15. Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–63

    Article  PubMed  CAS  Google Scholar 

  16. Tune LE, Wong DF, Pearlson GD. Elevated dopamine D2 receptor density in 23 schizophrenic patients: a positron emission study with [11C]n-methylspiprone. Schizophr Res 1992; 6: 147–52

    Google Scholar 

  17. Farde L, Wiesel FA, Stone-Elanders, et al. D2 receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47: 213–9

    Article  PubMed  CAS  Google Scholar 

  18. Pearlson GD, Tune LE, Wong DF, et al. Quantitative D2 dopamine receptor PET and structural MRI changes in late onset schizophrenia. Schizophr Bull 1994; 19: 783–95

    Google Scholar 

  19. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 32: 229–313

    PubMed  CAS  Google Scholar 

  20. Waddington JL. Mechanisms of action of typical and atypical antipsychotic drugs in the treatment of schizophrenia. Clinician 1993; 11: 45–54

    Google Scholar 

  21. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. Arch General Psychiatry 1988; 45: 789–96

    Article  CAS  Google Scholar 

  22. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 2: 192–202

    Google Scholar 

  23. Bunney BS. Clozapine: a hypothesized mechanism for its unique clinical profile. Br J Psychiatry 1992; 160 (17 Suppl.): 17–21

    Google Scholar 

  24. Farde L, Wiesel FA, Nordstrom AL, et al. D1 and D2 receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989; 99 Suppl.: S28–S31

    Article  PubMed  Google Scholar 

  25. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 160 (17 Suppl.): 22–9

    Google Scholar 

  26. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor, with a high affinity for neuroleptic clozapine. Nature 1991; 350: 610–4

    Article  PubMed  Google Scholar 

  27. NIMH (National Institute of Mental Health) Psychopharmacology Service Centre Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246–61

    Article  Google Scholar 

  28. Goldberg SC. Negative and deficit symptoms do respond to neuroleptics. Schizophr Bull 1985; 11: 453–6

    PubMed  CAS  Google Scholar 

  29. Jeste D. Treatment of late life schizophrenia with neuroleptics. Schizophr Bull 1994; 19: 817–31

    Google Scholar 

  30. Post F. Persistent persecutory states of the elderly. Oxford: Pergamon, 1966

    Google Scholar 

  31. Rabins P, Pauker S, Thomas J. Can schizophrenia begin after age 44? Compr Psychiatry 1984; 25: 290–3

    Article  PubMed  CAS  Google Scholar 

  32. Pearlson GD, Kreger L, Rabins PV, et al. A chart review study of late onset and early onset schizophrenia. Am J Psychiatry 1989; 146: 1568–74

    PubMed  CAS  Google Scholar 

  33. Howard R, Levy R. Which factors affect treatment response in late paraphrenia? Int J Geriatr Psychiatry 1992; 7: 667–72

    Article  Google Scholar 

  34. Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. 3rd ed. London: Balliere, Tindall, and Cassell, 1969

    Google Scholar 

  35. Mulsant BH, Gershon S. Neuroleptics in the treatment of psychosis in late life: a rational approach. Int J Geriatr Psychiatry 1992; 8: 979–92

    Article  Google Scholar 

  36. Swift CG, Triggs EJ. Clinical pharmacokinetics in the elderly. New York: Marcell Dekker, 1987: 31–82

    Google Scholar 

  37. Aoba A, Kakita Y, Yamaguchi N, et al. Absence of age effect on plasma haloperidol neuroleptic levels in psychiatric patients. J Gerontol 1985; 40:303–8

    PubMed  CAS  Google Scholar 

  38. Cohen BM, Sommer BR. Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8: 336–9

    PubMed  CAS  Google Scholar 

  39. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72

    Article  PubMed  CAS  Google Scholar 

  40. Wilson JA, MacLennan WJ. Review: drug induced Parkinsonism in elderly patients. Age Ageing 1989; 18: 208–10

    Article  PubMed  CAS  Google Scholar 

  41. Marsden CD, Tarsy D, Baldessarini RJ. Spontaneous and drug induced movement disorder in psychotic patients. In: Benson DF, Blumer D, editors. Psychiatric aspects of neu rological disease. New York: Grune and Stratton, 1986: 219–66

    Google Scholar 

  42. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia incidence and risk factors. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 52–6

    Google Scholar 

  43. Smith JM, Balderssarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37: 1367–73

    Article  Google Scholar 

  44. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19: 303–15

    PubMed  CAS  Google Scholar 

  45. Schmidt G, Grohmann R, Strauss A, et al. Epidemiology of toxic delirium due to psychotropic drugs in psychiatric hospitals. Compr Psychiatry 1987; 28: 242–87

    Article  PubMed  CAS  Google Scholar 

  46. Blumenthal MD, Davie JW. Dizziness and falling in elderly psychiatric outpatients. Am J Psychiatry 1980; 137: 203–6

    PubMed  CAS  Google Scholar 

  47. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7

    Article  PubMed  CAS  Google Scholar 

  48. Schuster P, Gabriel E, Kufferle B. Reversal by physostigmine of clozapine induced delirium. Clin Toxicol 1977; 10: 437–41

    Article  PubMed  CAS  Google Scholar 

  49. Rosen J, Bohon S, Gershon S. Antipsychotics in the elderly. Acta Psychiatr Scand 1990; 82 Suppl. 358: 170–5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrie Services for Adults, Fulbourn Hospital, Cambridge, CB1 5EF, England

    Carol Gregory &  Peter McKenna

Authors
  1. Carol Gregory
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gregory, C., McKenna, P. Pharmacological Management of Schizophrenia in Older Patients. Drugs & Aging 5, 254–262 (1994). https://doi.org/10.2165/00002512-199405040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199405040-00003

Keywords

Search

Navigation